Volume 5, Issue 14: Agents for the management of Pseudomonas aeruginosa infection

e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.

(Volume 5, Issue 14)

 

Target Audience

Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to: 

  • Discuss optimal therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis
  • Describe the pathophysiology of pulmonary exacerbations associated with Pseudomonas infection in patients with cystic fibrosis
  • Evaluate the optimal choice of antibiotics to treat Pseudomonas-associated pulmonary exacerbations in patients with cystic fibrosis

 

Additional information
Contact email: 
ijhn@jhmi.edu
Course summary
Available credit: 
  • 0.50 ANCC
  • 0.50 Attendance
Registration opens: 
11/19/2015
Registration closes: 
11/18/2017
Cost:
$0.00
Shawn Aaron, MD
Senior Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Professor
Division Director- Respirology
University of Ottawa
Ottawa, Ontario CA
 

Disclosure

Dr. Shawn Aaron reports he has no relevant relationships with a commercial entity.

 

Unlabeled/Unapproved Uses

Dr. Shawn Aaron reports there will be discussions of off-label or unapproved uses including inhaled colistin, inhaled levofloxacin, inhaled ciprofloxacin, liposomal amikacin, doripenem, and sitafloxacin. 

 

Available Credit

  • 0.50 ANCC
  • 0.50 Attendance

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Make sure your Adobe flash is updated by clicking HERE.